Guggenheim Capital’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Guggenheim Capital’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-14,103	Closed	-$1.51M	–	1966
2023 Q1	$1.51M	Buy	14,103 +8,664	+159%	+$997K	0.01%	975
2022 Q4	$598K	Buy	+5,439	New	+$353K	0.01%	1404

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Guggenheim Capital's RXDX Position: Q2 2023 in Review

Guggenheim Capital sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 14,103 shares — an estimated $1.51M sold.

Guggenheim Capital first reported a position in RXDX in Q4 2022 and held it in 2 quarters. The position peaked at $1.51M in Q1 2023. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Guggenheim Capital reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Guggenheim Capital sold 14,103 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $1.51M.
Guggenheim Capital first reported a position in Prometheus Biosciences, Inc. Common Stock in Q4 2022 and held it in 2 quarters.
Guggenheim Capital's Prometheus Biosciences, Inc. Common Stock position peaked at $1.51M in Q1 2023.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Guggenheim Capital's 13F filing for Q2 2023, filed 11 Aug 2023.